Skip to content

Phibro Animal Health

US · PAHC #2966 by market cap Listed 1970
33.29 -0.79 -2.32%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:30

✦ Quant Financial Health how this is computed

Fair
  • Altman Z-Score is 2.99, in the 1.8-3.0 "grey zone".
  • Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.

✦ Quant Revenue Concentration how this is computed

Single-engine
  • Animal health is the largest reported line at 75.77% of revenue, across 3 reported segments.
  • The next-largest line, Mineral Nutrition, is a distant second at 19.02% - a sharp slowdown here would have little to offset it.

Revenue annual, last 8 years

Latest year +17.12% YoY

Margins

Gross margin
33.76%
Operating margin
12.81%
Net margin
6.57%

Key ratios & quality

PEG uses trailing P/E against the 3-year net income growth rate (45.15%/yr) since forward earnings estimates aren't available here, so this is not a "forward PEG." Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.

Income statement

Line item 2019 2020 2021 2022 2023 2024 2025 2026
Revenue 828.00M800.35M833.35M942.26M977.89M1.02B1.30B1.52B
Gross profit 264.62M256.88M271.38M285.40M298.24M313.09M399.94M512.52M
Selling & admin expenses 181.40M187.69M196.51M206.41M226.39M259.78M289.48M318.12M
Research & development ----------------
Operating profit 83.23M69.19M74.87M78.99M71.85M53.32M110.47M194.40M
Pretax profit 71.51M55.51M66.47M72.33M54.07M10.92M67.99M137.35M
Tax 16.79M21.96M12.08M23.15M21.47M8.50M19.73M37.63M
Net profit 54.71M33.55M54.39M49.18M32.61M2.42M48.26M99.72M
Basic EPS 11111012
Diluted EPS 1.350.831.341.210.810.061.192.43

Balance sheet

Line item 2019 2020 2021 2022 2023 2024 2025 2026
Total current assets 466.16M451.84M498.91M566.23M585.72M601.00M810.61M935.51M
Cash & ST investments 81.57M91.34M93.21M91.25M81.28M114.61M77.04M81.99M
Inventory 198.32M196.66M216.31M259.16M277.57M265.91M444.43M534.88M
Total assets 726.67M784.10M841.33M931.70M971.40M982.18M1.36B1.50B
Total current liabilities 154.23M157.24M164.12M190.83M176.00M204.15M293.47M316.47M
Short-term debt 12.54M25.19M15.99M21.05M28.35M37.26M25.38M35.60M
Long-term debt 313.64M368.26M382.71M417.93M452.54M458.29M702.44M707.77M
Total liabilities 510,656,000.00595,896,000.00602,796,000.00669,257,000.00688,888,000.00725,543,000.001,075,218,000.001,115,764,000.00
Total equity 216.02M188.20M238.53M262.44M282.51M256.64M285.68M385.48M
Retained earnings 168.93M183.06M218.02M247.75M260.91M243.89M272.70M352.96M

Cash flow

Line item 2019 2020 2021 2022 2023 2024 2025 2026
Operating cash flow 47.17M59.35M48.31M31.65M13.31M87.59M80.12M68.95M
Depreciation & amortization 27.56M32.34M31.88M32.71M34.01M36.18M45.61M51.51M
Free cash flow 17.28M25.30M18.99M-5.40M-38.48M46.36M41.83M9.87M
Dividends paid -18.59M-19.42M-19.43M-19.44M-19.44M-19.44M-19.45M-19.46M
Stock buybacks / issuance 1.13M--------------
Ending cash balance 57.57M36.34M50.21M74.25M41.28M70.61M68.04M61.42M

Returns & efficiency

Line item 2019 2020 2021 2022 2023 2024 2025 2026
ROE % 27.2916.6025.4919.6311.970.9017.8029.72
ROA % 7.834.446.695.553.430.254.126.97
ROIC % 12.267.1510.148.135.431.967.6511.73
5-year avg ROE % 105.2854.7532.2925.5220.2014.9215.1616.00
EBIT margin % 10.298.659.508.967.363.237.8111.95
FCF / sales % 2.093.162.28----4.563.230.65
Current ratio 3.022.873.042.973.332.942.762.96
Quick ratio 1.561.391.461.351.391.391.041.01
Debt / assets 44.8952.3850.7250.5052.5053.5055.9652.54
LT debt / equity 145.19204.85172.19171.25170.48190.23257.69195.39
Interest coverage 6.235.046.236.984.011.503.044.11
Revenue CAGR (3Y) % 3.281.550.544.406.916.8911.2215.79
Net income CAGR (3Y) % -12.87-19.62-5.71-3.49-0.95-64.58-0.6245.15
FCF CAGR (3Y) % 171.22-31.14-28.28----34.66----

Revenue breakdown most recent period

Business

Animal health75.77%
Mineral Nutrition19.02%
Performance products5.21%

Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.

Phibro Animal Health discussion 0 comments

Add a comment